

1           **ScalaFlux: a scalable approach to quantify fluxes in metabolic subnetworks**

2

3     Pierre Millard<sup>1</sup>, Uwe Schmitt<sup>2</sup>, Patrick Kiefer<sup>3</sup>, Julia A. Vorholt<sup>3</sup>, Stéphanie Heux<sup>1</sup> and Jean-

4                                 Charles Portais<sup>1,4,5,\*</sup>

5

6     <sup>1</sup>TBI, Université de Toulouse, CNRS, INRA, INSA, Toulouse, France

7     <sup>2</sup>Scientific IT Services, ETH Zurich, 8092, Zurich, Switzerland

8     <sup>3</sup>Institute of Microbiology, Department of Biology, ETH Zurich, 8093, Zurich, Switzerland

9     <sup>4</sup>MetaToul-MetaboHUB, National infrastructure of metabolomics and fluxomics, Toulouse,  
10    France

11    <sup>5</sup>STROMALab, Université de Toulouse, INSERM U1031, EFS, INP-ENVT, UPS, Toulouse,  
12    France

13

14    \* Corresponding author

15    E-mail: jean-charles.portais@insa-toulouse.fr

16

17    Short title: ScalaFlux: scalable isotope-based metabolic flux analysis

18 **Abstract**

19

20  $^{13}\text{C}$ -metabolic flux analysis ( $^{13}\text{C}$ -MFA) allows metabolic fluxes to be quantified in living  
21 organisms and is a major tool in biotechnology and systems biology. Current  $^{13}\text{C}$ -MFA  
22 approaches model label propagation starting from the extracellular  $^{13}\text{C}$ -labeled nutrient(s),  
23 which limits their applicability to the analysis of pathways close to this metabolic entry point.  
24 Here, we propose a new approach to quantify fluxes through any metabolic subnetwork of  
25 interest by modeling label propagation directly from the metabolic precursor(s) of this  
26 subnetwork. The flux calculations are thus purely based on information from within the  
27 subnetwork of interest, and no additional knowledge about the surrounding network (such as  
28 atom transitions in upstream reactions or the labeling of the extracellular nutrient) is required.  
29 This approach, termed ScalaFlux for SCALAbile metabolic FLUX analysis, can be scaled up  
30 from individual reactions to pathways to sets of pathways. ScalaFlux has several benefits  
31 compared with current  $^{13}\text{C}$ -MFA approaches: greater network coverage, lower data  
32 requirements, independence from cell physiology, robustness to gaps in data and network  
33 information, better computational efficiency, applicability to rich media, and enhanced flux  
34 identifiability. We validated ScalaFlux using a theoretical network and simulated data. We  
35 also used the approach to quantify fluxes through the prenyl pyrophosphate pathway of  
36 *Saccharomyces cerevisiae* mutants engineered to produce phytoene, using a dataset for which  
37 fluxes could not be calculated using existing approaches. A broad range of metabolic systems  
38 can be targeted with minimal cost and effort, making ScalaFlux a valuable tool for the  
39 analysis of metabolic fluxes.

40 **Author Summary**

41

42 Metabolism is a fundamental biochemical process that enables all organisms to operate and  
43 grow by converting nutrients into energy and ‘building blocks’. Metabolic flux analysis  
44 allows the quantification of metabolic fluxes *in vivo*, i.e. the actual rates of biochemical  
45 conversions in biological systems, and is increasingly used to probe metabolic activity in  
46 biology, biotechnology and medicine. Isotope labeling experiments coupled with  
47 mathematical models of large metabolic networks are the most commonly used approaches to  
48 quantify fluxes within cells. However, many biological questions only require flux  
49 information from a subset of reactions, not the full network. Here, we propose a new approach  
50 with three main advantages over existing methods: better scalability (fluxes can be measured  
51 through a single reaction, a metabolic pathway or a set of pathways of interest), better  
52 robustness to missing data and information gaps, and lower requirements in terms of  
53 measurements and computational resources. We validate our method both theoretically and  
54 experimentally. ScalaFlux can be used for high-throughput flux measurements in virtually any  
55 metabolic system and paves the way to the analysis of dynamic fluxome rearrangements.

56 **Introduction**

57

58 Metabolic flux analysis (MFA) with stable isotope tracers, typically a  $^{13}\text{C}$ -labeled carbon  
59 source, allows intracellular fluxes to be quantified in a wide range of organisms and is now a  
60 major tool in the fields of biotechnology [1-3], systems biology [4-6] and medicine [7, 8].  
61 Current approaches rely on isotopic models to simulate tracer propagation through metabolic  
62 networks [1, 9-14]. Fluxes are then estimated by fitting experimental concentrations and  
63 isotopic profiles of metabolites. Current simulation frameworks require known and constant  
64 label input(s). The only constant label input(s) is (are) the isotopically-labeled nutrient(s) in  
65 the extracellular medium, which must therefore be included in the flux model. This  
66 requirement also applies to alternative  $^{13}\text{C}$ -MFA frameworks, such as metabolic flux ratio  
67 analysis [15, 16] and kinetic flux profiling [17]. In practice, this means that all metabolic  
68 models must explicitly include the labeled nutrient(s) initially provided to the biological  
69 system and all the pathways that distribute the isotopic tracer up to the pathway of interest. To  
70 ensure fluxes are identifiable, the extracellular fluxes and the intracellular concentrations and  
71 labeling of upstream metabolites must also be measured. This is a major limitation for  
72 investigating i) pathways far downstream of the labeled nutrient(s), ii) networks with reaction  
73 gaps (e.g. an uncertain network topology), iii) incomplete datasets, iv) experiments performed  
74 in rich media, or v) situations where the isotopic transitions remain uncertain or complex (e.g.  
75  $^2\text{H}$  tracer) [1, 18]. This also makes the entire experimental and computational workflow very  
76 time consuming, costly and error prone. Overall, the modeling requirement that the tracer has  
77 to be propagated right from the extracellular nutrient limits the application of flux  
78 measurements to pathways closely related to the label input. The vast majority of existing  $^{13}\text{C}$ -  
79 flux studies focus indeed on central carbon metabolism, and most  $^{15}\text{N}$ -flux studies focus on

80 the nitrogen assimilation network [1, 4, 6, 17, 19]. There is therefore a need for more robust  
81 and scalable approaches to quantify metabolic fluxes in biochemical systems.

82 Here, we propose a new isotope-based-MFA approach, named ScalaFlux, to measure fluxes at  
83 the level of any metabolic subnetwork of interest, in which label propagation is modeled  
84 directly from the metabolic precursor(s) of this subnetwork. ScalaFlux uses a limited amount  
85 of input data and increases the number of pathways that can be accessed, while significantly  
86 reducing experimental and computational requirements. We demonstrate the value of  
87 ScalaFlux with *in silico* simulations and its practical applicability by quantifying *in vivo*  
88 fluxes in the yeast prenyl pyrophosphate pathway.

89


## 90 **Results**

91

### 92 *Basic principle: reconsidering label inputs*

93 Understanding the basic principle of the proposed approach requires some concepts and  
94 terminology that are introduced and illustrated using the example network shown in Fig 1.  
95 This network of 18 metabolites and 20 reactions includes three topological motifs classically  
96 found in metabolism: a linear pathway, a branching node and a cycle. We refer to the initial  
97 source(s) of label – i.e. the extracellular nutrient(s), here  $X_{out}$  – as the *global label input(s)* for  
98 the metabolic network. After  $X_{out}$  is switched from natural abundance to isotopically labeled,  
99 the isotopic tracer propagates through the metabolic network and the intracellular metabolites  
100 ( $X_{in}, A, \dots, O$ ), which are progressively labeled as a function of metabolite concentrations and  
101 fluxes. Fluxes can then be estimated using a model-based approach by minimizing the  
102 difference between experimental labeling data and the labeling profiles simulated by the  
103 model.

104



105

106 **Fig 1. Principle of ScalaFlux.** Panel A shows an example network in the Systems Biology  
 107 Graphical Notation format (SBGN, [www.sbgn.org](http://www.sbgn.org)) [20] to illustrate the basic principle of  
 108 ScalaFlux. The flux models (and associated datasets) required to quantify the flux through  
 109 reaction r16 using classical non-stationary <sup>13</sup>C-MFA and ScalaFlux are compared in panel B.  
 110 The ScalaFlux model, the set of measurements required for the flux calculation, and the flux  
 111 calculation workflow are shown in panel C.

112

113 Current non-stationary <sup>13</sup>C-flux calculation frameworks require constant label input(s) so the  
 114 global label input(s) must be included in the flux models. To specifically measure the flux  
 115 through reaction r16 in the example network, the flux model (red boundaries in Fig 1A) must  
 116 contain X<sub>out</sub> and all the reactions that contribute to isotope propagation up to the product of  
 117 r16. This flux model includes a total of 17 reactions, 1 (global) label input and 14 metabolic  
 118 intermediates (Fig 1B). Measurements of metabolite concentrations and labeling at several  
 119 nodes of the network as well as of extracellular fluxes and biomass composition are required  
 120 to calculate the flux.

121 We propose a more scalable  $^{13}\text{C}$ -flux approach, named ScalaFlux for SCALable metabolic  
122 FLUX analysis, to quantify fluxes through a subnetwork of interest using internal information  
123 from this network only. ScalaFlux does not require data on the extracellular labeled nutrient,  
124 upstream metabolites, or any other knowledge about the surrounding network. The flux model  
125 encodes a metabolic subsystem (i.e. a subset of the cellular metabolic network) and  
126 specifically contains the reaction(s) of interest, as illustrated in Fig 1 and described in detail  
127 below. All the metabolic substrates in this subsystem are considered *local label inputs*, and  
128 label propagation is simulated directly from these local label inputs. If the reaction of interest  
129 is r16, the labeling dynamics of  $M$  is defined as the local label input of the corresponding  
130 subsystem to simulate the labeling dynamics of  $N$ . In contrast to global label inputs, which are  
131 constant, known and controlled, the labeling of local label inputs changes with time, is not  
132 known *a priori* and cannot be controlled. Label incorporation can nevertheless be determined  
133 experimentally and be used for the downstream reactions. Using these discrete measurements  
134 as direct label inputs for simulations would result in sharp changes in label input at each  
135 measurement time and thereby yield stiff equations and simulation artifacts. The first step of  
136 the ScalaFlux workflow (Fig 1C) therefore consists in transforming the discrete measurements  
137 into a continuous (time-dependent) representation by fitting analytical functions, ensuring  
138 smooth variations as a function of time. A system of ordinary differential equations (ODEs)  
139 can then be constructed using conventional frameworks to simulate label propagation from  
140 the local label input(s). By combining this simulation approach with optimization routines,  
141 fluxes can be estimated by fitting experimental data. This workflow has been implemented in  
142 a major update of IsoSim [21] (see *Methods* for details).

143 Importantly, the studied subsystem can include larger parts of the network, as detailed in the  
144 following sections. This means that any given (set of) flux(es) can be quantified  
145 independently of the rest of the metabolic network, with no additional measurements

146 (extracellular fluxes, growth rates, biomass composition, concentrations and labeling of  
147 upstream metabolites), and independently of the (often incomplete) knowledge of the  
148 metabolic network outside the boundaries of the subsystem under study.

149 ScalaFlux exploits many concepts from non-stationary  $^{13}\text{C}$ -MFA and thus benefits directly  
150 from recent advances in the field, such as efficient mathematical frameworks for experimental  
151 design [13, 14, 22-24], simulation [14, 25-27], optimization [10, 28] and sensitivity analysis  
152 [14, 29]. Because it is based on detailed modeling of isotope propagation, ScalaFlux is generic  
153 with respect to the network topology (flux models can include branching nodes, cycles, or any  
154 other of the topological motifs that compose metabolic networks), the isotopic tracer ( $^2\text{H}$ ,  $^{13}\text{C}$ ,  
155  $^{15}\text{N}$ , etc), and the type of isotopic measurement (MS, MS/MS, NMR, etc). The flux analyses  
156 presented in the rest of the article are based on mean molecular enrichment data collected by  
157 mass spectrometry in  $^{13}\text{C}$ -labeling experiments.

158


### 159 *Construction of flux models*

160 Flux models must precisely describe the topology of the subnetwork of interest while ensuring  
161 independence from the surrounding network. A generic procedure is presented in this section  
162 to streamline the construction of self-consistent flux models of any part of a metabolic  
163 network.

164 We define a *minimal subsystem*  $S_Y$  as the minimal set of reactions required to simulate the  
165 labeling dynamics of a given metabolite  $Y$ . A metabolic network containing  $n$  metabolic  
166 intermediates can thus be decomposed into  $n$  minimal subsystems. The minimal subsystem  $S_Y$   
167 must include all the reactions that produce  $Y$  (since they may all affect its labeling dynamics),  
168 with their substrates corresponding to local label inputs. For practical modeling reasons, a  
169 sink reaction consuming  $Y$  has to be included to avoid its accumulation, in keeping with the  
170 metabolic steady-state assumption (i.e. metabolite concentrations are constant). Each minimal



171 subsystem is self-consistent and can be incorporated into a flux model to estimate fluxes  
 172 through the included reactions. This modular representation is the essence of the scalability of  
 173 ScalaFlux. We used this procedure to decompose the example network shown in Fig 1A into  
 174 17 minimal subsystems, as shown in Fig 2A. Note that reaction r6, which is reversible, is  
 175 present in two subsystems ( $S_B$  and  $S_C$ ) to account for its forward and reverse fluxes [21].  
 176



177  
 178 **Fig 2. Network decomposition to construct flux models.** The metabolic network shown in  
 179 Fig 1A can be decomposed into 17 minimal subsystems (panel A) which are sufficient to  
 180 simulate the labeling dynamics of metabolic intermediates (green circles) from the local label  
 181 input(s) (red circles). Each minimal subsystem is self-consistent and can be used for  
 182 independent flux calculations. These minimal subsystems can also be combined to analyze  
 183 larger subsystems, as shown in panels B and C.

184

185 To analyze larger subnetworks that include several reactions of interests, the individual  
 186 minimal subsystems that compose this subnetwork should be combined (Fig 2). Two  
 187 subsystems can be combined when they share a common metabolite, e.g. the two minimal  
 188 subsystems  $S_Y$  and  $S_Z$  can be merged if  $Y$  is a local label input of  $Z$ . The local label inputs of  
 189 the resulting subsystem  $S_{YZ}$  are all the local label inputs except  $Y$ , which is now an  
 190 intermediate of  $S_{YZ}$ . This ensures that all the reactions (and local label inputs) that contribute

191 to the labeling dynamics of  $Y$  and  $Z$  are included. For instance, to quantify fluxes through the  
192 set of reactions  $\{r_4, r_9, r_{16}, r_{17}, r_{18}\}$  in the example network,  $S_O$  can first be united with  $S_N$   
193 (since the metabolic intermediate  $N$  is a local label input of  $S_O$ ) (Fig 2B), and the resulting  
194 subsystem  $S_{NO}$  can then be merged with  $S_F$  (Fig 2C). The final subsystem  $S_{FNO}$  contains all the  
195 reactions of interest and has three local label inputs ( $A$ ,  $E$  and  $M$ ) and three intermediates ( $F$ ,  
196  $N$  and  $O$ ).


197

### 198 *Flux calculation in minimal metabolic subsystems*

199 The minimal set of measurements required to estimate fluxes in a minimal subsystem  $S_Y$   
200 consists of i) the labeling dynamics of its local label input(s) (used to simulate tracer  
201 propagation) and ii) the labeling dynamics of  $Y$  (used for flux estimation). These transient  
202 label dynamics are thus sufficient to estimate the turnover rate of  $Y$ , i.e. the ratio between its  
203 pool and its biosynthetic flux. In a branched pathway, this information is also sufficient to  
204 determine the contribution of each converging reaction to the biosynthesis of  $Y$ . Absolute  
205 fluxes can be estimated when the absolute concentration of  $Y$  is available. The absolute *in vivo*  
206 flux through a given reaction in any linear pathway can thus be estimated from reactant data  
207 alone.

208 ScalaFlux was tested on the metabolic network shown in Fig 1A. Metabolite concentrations  
209 and fluxes were initialized at the values listed in the Supporting information (S1 Table), and  
210 label propagation through this network was simulated to create a theoretical dataset (S1 Fig).  
211 We estimated fluxes in all minimal subsystems (Fig 3A) from these theoretical labeling  
212 dynamics. The transient  $^{13}\text{C}$ -enrichments of all local label inputs were accurately described by  
213 fitting a double logistic function (S2 Fig), and these analytical functions were used as label  
214 inputs for flux calculation.

215



216

217 **Fig 3. Fluxes through each reaction of the example network (Fig 1A) estimated by**  
218 **analyzing all minimal subsystems.** Fluxes were estimated independently in all the minimal  
219 subsystems shown in panel A. The estimated fluxes are in good agreement with the true  
220 values ( $R^2 = 0.98$ ,  $p\text{-value} = 1.10^{-14}$ , panel B). The distribution of fluxes estimated from 200  
221 noisy datasets are shown in panel C, with the true value used for simulation shown as a red  
222 dot and the median of the estimated fluxes shown as a white dot.

223

224 The labeling dynamics of metabolic intermediates are accurately fitted by the flux models for  
225 all minimal subsystems (S3 Fig). The estimated fluxes are in good agreement with the true  
226 values used to run the simulations ( $R^2 = 0.98$ , Fig 3B), with an average relative error of 7 %.  
227 For the reversible reaction r6, both the forward and reverse reaction rates were determined.  
228 The robustness of ScalaFlux to measurement noise was assessed by estimating fluxes from  
229 200 datasets in which Gaussian noise was added to the theoretical data, assuming a typical  
230 precision 0.02 for  $^{13}\text{C}$ -enrichments and of 10 % for concentrations [30, 31]. The distribution  
231 of fluxes estimated from these datasets indicates that the precision of the method is good, with  
232 an average relative standard deviation of 13 % (Fig 3C). ScalaFlux is thus robust to  
233 measurement uncertainty. Overall, the proposed approach provides accurate estimates of

234 absolute fluxes, with no measurement of extracellular uptake or production fluxes having  
235 been provided as input. This proof of concept example validates the proposed approach.


236

237 *From individual reactions to metabolic pathways: combining minimal subsystems enhances*  
238 *flux identifiability and precision*

239 As well as quantifying fluxes in minimal subsystems, ScalaFlux can be used to analyze larger  
240 subsystems. Just like in minimal subsystems, the set of measurements required to estimate  
241 fluxes in larger subsystems consists of i) the labeling dynamics of local label input(s) and ii)  
242 the labeling dynamics of (at least one) metabolic intermediate(s).

243 To illustrate the value of this scalability, we explored different options to estimate the flux  
244 through the pathway composed of the seven reactions {r10, ..., r16} (Fig 4A). We identified a  
245 total of 29 subsystems (and associated datasets, Fig 4B) that potentially enable flux evaluation  
246 through this pathway. Of course, this flux can be estimated through each reaction  
247 individually, as demonstrated above, corresponding to subsystems  $S_G$ ,  $S_H$ ,  $S_{IJ}$ ,  $S_K$ ,  $S_L$ ,  $S_M$ , and  
248  $S_N$  in Fig 4B. Several reactions in this pathway can also be combined into a single flux model  
249 (following the rules defined in section *Construction of flux models*), e.g. by merging two  
250 connected subsystems as done for subsystems  $S_{GH}$ ,  $S_{HK}$ ,  $S_{LM}$  and  $S_{MN}$ .

251



252

253 **Fig 4. Demonstration of the scalability of ScalaFlux.** The absolute flux through the  
 254 pathway r10-r16 (orange reactions in panel A) can be quantified in 29 different subsystems  
 255 (columns in panel B), each of which i) include different reactions (in blue) and ii) exploit  
 256 different sets of measurements (labeling of local label inputs in red, and concentrations and  
 257 labeling of metabolic intermediates in green). The fluxes estimated for each subsystem are  
 258 shown in panel C and are compared to the true value (1, horizontal line).

259

260 The fluxes calculated for each subsystem are shown in Fig 4C and are all close to the true  
261 value (1.0). Increasing the size of the subsystem used for flux calculation improves both the  
262 accuracy and precision of the estimated fluxes. For instance, the flux was estimated at  
263  $0.96 \pm 0.10$  for the minimal subsystem  $S_G$  and at  $0.99 \pm 0.04$  for the largest subsystem  $S_{GHIJKLM}$ .  
264 This is because the reconciliation of larger datasets during flux calculation increases the  
265 robustness of the approach. Experimental and analytical efforts can thus be optimized  
266 depending on the required flux precision.


267 Another advantage of this scalability is that it increases flux identifiability. For instance,  
268 estimating the flux through  $r16$  is possible via the flux model of  $S_N$ , provided the labeling  
269 dynamics of  $M$  is available (Fig 4B). If  $M$  cannot be measured, label propagation cannot be  
270 simulated and no flux can be estimated. However, if the labeling dynamics of  $L$  is available,  
271 the flux through  $r16$  can still be estimated using the flux model of  $S_{MN}$  for which the labeling  
272 dynamics of the local label input  $L$  is known. The most appropriate flux model can thus be  
273 selected based on the available data, without making the additional assumptions or  
274 oversimplifications required by current approaches (e.g. using hypothetical tracer atom  
275 transitions from upstream pathways, defining reversible reactions as irreversible, or lumping  
276 reactions). Since each subsystem can be investigated independently of the rest of the cellular  
277 network, poorly identified parts of the network (e.g. due to missing measurements or an  
278 uncertain topology) do not affect the reaction(s) of interest.

279

### 280 *Biosynthesis of prenyl pyrophosphates in yeast*

281 ScalaFlux provides the opportunity to reconsider published datasets from which fluxes could  
282 not be calculated because of the lack of an appropriate modeling framework. As an example  
283 application, we analyzed a published dataset on the metabolism of prenyl pyrophosphates, the

284 precursors of isoprenoids, in the yeast *Saccharomyces cerevisiae* [32]. Isoprenoid  
 285 biosynthesis starts with isopentenyl pyrophosphate (IPP), which is isomerized into  
 286 dimethylallyl pyrophosphate (DMAPP) (Fig 5A). DMAPP is then condensed with another  
 287 IPP to generate geranyl pyrophosphate (GPP). Longer prenyl pyrophosphates are built by  
 288 successive condensation of IPP onto each intermediate, giving farnesyl pyrophosphate (FPP)  
 289 from GPP and geranylgeranyl pyrophosphate (GGPP) from FPP.



290

291 **Fig 5. <sup>13</sup>C-metabolic flux analysis of prenyl pyrophosphate biosynthesis in**  
 292 *Saccharomyces cerevisiae* (wild type, S037 and S023 strains). The yeast prenyl  
 293 pyrophosphate pathway contains five reactions for the successive condensation of IPP (in

294 grey) onto each intermediate (DMAPP, FPP, GPP and GGPP) (**A**). The labeling dynamics of  
295 IPP were fitted with a double logistic function, which was used as the local label input. Fluxes  
296 were estimated by fitting the metabolite concentrations and transient  $^{13}\text{C}$ -enrichments of GPP,  
297 FPP and GGPP. Experimental and fitted data are shown for each strain in panel **B** for the  
298 labeling dynamics (dots: experimental values; lines: best fit) and in panel **C** for the metabolite  
299 concentrations. The fluxes estimated in each strain are given with their standard deviations in  
300 panel **D**. The GGPP demand calculated from phytoene accumulation in strain S023 is shown  
301 in grey for comparison. The GGPP turnover rate estimated in each strain is shown in panel **E**.  
302

303 The published dataset contains i) steady-state concentrations of three prenyl pyrophosphate  
304 intermediates (GPP, FPP and GGPP) measured during exponential growth on glucose and ii)  
305 44 transient  $^{13}\text{C}$ -enrichments following a switch from unlabeled to U- $^{13}\text{C}$ -glucose (11 time  
306 points for GPP, FPP, GGPP, and combined pools of IPP and DMAPP). These data were  
307 collected in three different strains designed to enhance phytoene production. The GGPP pool  
308 of the wild-type (WT) metabolic chassis was first increased by constructing the strain S037,  
309 which overexpresses GPP and FPP synthase (ERG20) and GGPP synthase (CrtE). A  
310 heterologous phytoene synthase (CrtB from *Pantoea ananatis*) was then expressed to convert  
311 GGPP into phytoene in strain S023. The pools of all intermediates were higher in strains S037  
312 and S023 compared to wild type, suggesting higher fluxes, but this could not be verified  
313 because fluxes could not be inferred solely from these data. We therefore used ScalaFlux to  
314 estimate the *in vivo* flux through the prenyl pyrophosphate pathway in the three strains.

315 The flux model is centered on the specific pathway of interest and thus only includes the five  
316 reactions shown in Fig 5A. We used a double logistic function to fit the transient labeling  
317 dynamics of IPP (i.e. mean molecular  $^{13}\text{C}$ -enrichment), from which accurate analytical  
318 representations were obtained (Fig 5B). This function was used as label input to estimate



319 fluxes by fitting the concentrations and dynamic  $^{13}\text{C}$ -enrichments of three other intermediates  
320 (GPP, FPP and GGPP). The good agreement between simulations and measurements (Figs 5B  
321 and 5C,  $R^2 > 0.98$ ) indicates that the concentrations and isotopic data are consistent with the  
322 topology defined in the model. In wild-type *Saccharomyces cerevisiae*, the GGPP  
323 biosynthetic flux was estimated at  $0.15 \pm 0.01$  nmol/g<sub>DCW</sub>/min during exponential growth on  
324 glucose (Fig 5D). It increased to  $0.94 \pm 0.04$  nmol/g<sub>DCW</sub>/min in strain S037, hence confirming  
325 the relevance of the strain design strategy in improving the availability of GGPP, the  
326 precursor of phytoene biosynthesis. The flux was similar in the phytoene producing strain  
327 S023 ( $0.93 \pm 0.04$  nmol/g<sub>DCW</sub>/min). This indicates that the increased demand for GGPP does  
328 not propagate upstream and does not affect its production, in agreement with the low  
329 reversibility of the prenyl transferase reactions. Importantly, we verified that the flux  
330 estimated by ScalaFlux in S023 was consistent with the GGPP demand for phytoene synthesis  
331 estimated from phytoene accumulation ( $1.33 \pm 0.16$  nmol/g<sub>DCW</sub>/min, Fig 5D). The good  
332 agreement between these two independent methods demonstrates that ScalaFlux provides  
333 accurate flux measurements from datasets collected on just a few metabolic intermediates.  
334 Finally, while qualitative interpretations suggested that the turnover rate of GGPP was stable  
335 in the different strains [32], this could not be verified because the fluxes could not be  
336 estimated. We therefore evaluated this hypothesis by calculating the GGPP turnover from the  
337 estimated fluxes and metabolite concentrations. Results indicate that GGPP turnover (Fig 5E)  
338 is indeed very similar in the three strains (WT:  $12.7 \pm 0.1$ , S037:  $14.0 \pm 1.3$ , S023:  $11.9 \pm 0.5$  min<sup>-1</sup>),  
339 and thus confirm quantitatively that the GGPP pool increases roughly proportionally to its  
340 biosynthetic flux.

341

## 342 **Discussion**

343

344 In current  $^{13}\text{C}$ -MFA approaches, label propagation has to be modeled starting from the  
345 extracellular nutrient(s), which limits their applicability to flux analysis of pathways close to  
346 this nutrient. Here, we present a novel MFA framework to investigate any reaction or set of  
347 reactions in a subnetwork of interest based on just a few targeted measurements in this  
348 subnetwork.

349 The scalability of ScalaFlux stems from the modular decomposition of metabolic networks  
350 into minimal subsystems, which can be analyzed independently or merged together to analyze  
351 larger subnetworks, as demonstrated using a theoretical network and simulated data. The  
352 guidelines provided to decompose a network into minimal subsystems enable intuitive  
353 reasoning and facilitate experimental design (e.g. in terms of the measurements to perform),  
354 which can be supported further by *in silico* simulations. It is important to note that flux  
355 identifiability depends on the experimental setup used (e.g. type of isotopic data, accessible  
356 measurements, sampling frequency) and on biological constraints (e.g. network topology,  
357 fluxes). We refer to previous work [12-14, 22, 24, 33] for extensive discussion on these  
358 topics.

359 We validated the practical applicability of ScalaFlux by reanalyzing a published dataset on the  
360 metabolism of prenyl pyrophosphates, from which fluxes could not be calculated using  
361 current MFA approaches. Indeed, GGPP is continuously used by different processes (such as  
362 protein geranylgeranylation and membrane biosynthesis) and does not accumulate in cells. Its  
363 biosynthetic flux cannot therefore be measured *in vivo* without using isotopic tracers.  
364 Moreover, measuring this flux using stationary  $^{13}\text{C}$ -MFA approaches would have been  
365 impossible because of the topology of the prenyl pyrophosphate pathway. Non-stationary  $^{13}\text{C}$ -  
366 MFA approaches could have been used, but at much higher analytical and computational  
367 costs. The underlying model would have had to include many additional reactions involved in  
368  $^{13}\text{C}$  label propagation from glucose up to IPP, i.e. at least some of the central metabolic

369 pathways that contribute to the labeling of acetylCoA (glycolysis, the pentose phosphate  
370 pathway, and possibly anaplerotic reactions and the TCA cycle), and the entire mevalonate  
371 pathway that produces IPP from acetylCoA. This model would thus have contained several  
372 dozen reactions, for which the associated fluxes would have had to be estimated. Our  
373 approach significantly reduces the size of the model and the number of free parameters, and  
374 thereby the computational cost of the flux calculation. Moreover, the absolute pathway flux  
375 was estimated using the metabolite concentrations and  $^{13}\text{C}$ -enrichments collected for just a  
376 few metabolites using a single LC-HRMS platform [32]. Using traditional approaches, the full  
377 model would have been undetermined - and no flux could have been estimated - without  
378 additional experimental data on key points in the upstream pathways (e.g. the glucose uptake  
379 flux, and the pools and transient  $^{13}\text{C}$ -enrichments of upper intermediates), collected with  
380 different sampling times, and analyzed with different analytical platforms. Our approach thus  
381 also reduces experimental costs and processing efforts.

382 ScalaFlux is fundamentally scalable, providing several different ways to quantify a given (set  
383 of) flux(es). The most appropriate flux model should be selected based on the biological  
384 question to be addressed (e.g. in terms of the fluxes to be measured or the required flux  
385 precision) and practical constraints (e.g. network knowledge or available data). For instance,  
386 fluxes through individual reactions in a linear pathway can be estimated independently using  
387 different datasets. ScalaFlux can thus potentially verify (or disprove) assumptions that are  
388 usually made in  $^{13}\text{C}$ -MFA (e.g. that all the reactions in a given linear pathway carry the same  
389 flux) and to identify gaps in the current knowledge (e.g. that an intermediate of an apparently  
390 linear pathway is actually consumed by another unknown reaction, or that the assumed  
391 network topology is not sufficient to explain the labeling dynamics of some of the  
392 intermediates).

393 ScalaFlux is also highly versatile in terms of the pathways that can be monitored. It can be  
394 used to measure fluxes through virtually any metabolic subsystem of interest: a single  
395 reaction, a pathway, or larger networks. Because it exploits concepts from non-stationary  $^{13}\text{C}$ -  
396 MFA, ScalaFlux can be used to investigate  $\text{C}_1$ -metabolism (e.g.  $\text{CO}_2$  fixation, methylotrophy,  
397 folate metabolism). It also allows the quantification of metabolic fluxes that are currently  
398 difficult to measure, e.g. in secondary metabolism (such as prenyl pyrophosphate  
399 biosynthesis, as demonstrated here), or the biosynthesis of co-factors (e.g. ATP or NADPH)  
400 or other global regulators (e.g. ppGpp). Its scalability offers new possibilities for high-  
401 throughput flux profiling of a broad range of metabolic (sub)systems, at minimal cost and  
402 effort. ScalaFlux can easily be adapted to measure fluxes through other biological processes,  
403 such as protein turnover.

404 Overall, in addition to broadening the range of metabolic systems that can be investigated,  
405 ScalaFlux enhances the following aspects of  $^{13}\text{C}$ -MFA: minimal data and analytical  
406 requirements (fluxes can be estimated robustly from just a few measurements from the  
407 metabolic subsystem of interest, which can typically be collected using a single platform since  
408 closely related metabolites often have similar physico-chemical properties); independence  
409 from physiology (no need to measure nutrient uptake fluxes, growth rates, or biomass  
410 compositions); computational efficiency and stability (smaller equation systems with fewer  
411 free parameters); short labeling times (no tracer incorporation required to reach steady state),  
412 which allows dynamically changing fluxes to be probed; applicability to rich media (where  
413 measuring the many extracellular fluxes and labeling patterns of all the nutrients is difficult  
414 and may create computational bottlenecks); and better flux identifiability (because of its  
415 intrinsic scalability and robustness to missing measurements and network gaps).

416 ScalaFlux can be applied alone or in combination with other methods to address a broad range  
417 of biological questions. Combined with untargeted MS(/MS) approaches [34-36], ScalaFlux

418 paves the way to  $^{13}\text{C}$ -flux studies at the cellular level. The network coverage of untargeted  
419 MS(/MS) approaches is in general low and sparse, which results in poor flux identifiability  
420 when the complete dataset is integrated into metabolic reconstructions. In ScalaFlux,  
421 incomplete datasets can still be exploited to estimate fluxes through subsystems, and these  
422 flux measurements can be used to constrain genome scale metabolic models. Our approach  
423 should also be helpful to study poorly characterized organisms, for which simulations from  
424 carbon entry up to the pathway of interest may not be possible.

425 From a computational point of view, the proposed approach shares many elements with  
426 traditional approaches, and is compatible with all current simulation frameworks - EMUs,  
427 cumomers, fluxomers, etc - [1, 14, 25]. The approach introduced here can be implemented in  
428 existing  $^{13}\text{C}$ -flux calculation software [10, 26, 28, 37] with minimal effort. As proof of  
429 concept, we have implemented it in IsoSim, a versatile modeling software designed to  
430 integrate proteomics, metabolomics and isotopic data with stoichiometric, kinetic, regulatory  
431 and thermodynamic constraints to enhance functional analyses of metabolic systems.  
432 ScalaFlux is fully compatible with kinetic modeling, and thereby offers the possibility of  
433 analyzing dynamic fluxome rearrangements.

434

## 435 **Methods**

436

### 437 *Implementation of the ScalaFlux workflow*

438 We implemented the ScalaFlux workflow (Fig 1C) in a major update of IsoSim, an R  
439 software previously developed to couple kinetic and isotopic models of metabolism [21]. The  
440 source code of IsoSim v2 is freely distributed under open-source license at  
441 <https://github.com/MetaSys-LISBP/IsoSim/>.

442 Briefly, IsoSim includes functions to i) construct flux models, ii) design isotope labeling  
443 experiments, iii) define local label inputs, iv) simulate label propagation, and v) fit  
444 experimental data in order to estimate fluxes. Each of these steps is explained in detail in the  
445 following sections.

446 All the scripts we used to construct the models, to perform the simulations and to generate the  
447 figures are provided at <https://github.com/MetaSys-LISBP/IsoSim/> to ensure reproducibility  
448 and reusability.

449

#### 450 *Construction of flux models*

451 IsoSim requires the following information to construct a flux model: i) the set of reactions of  
452 interest, ii) the tracer atom transitions of each reaction, and iii) the accessible isotopic data.

453 IsoSim then automatically constructs the minimal system of ordinary differential equations  
454 (ODEs) required to simulate the accessible isotopic measurements. The detailed procedures  
455 and algorithms we used to construct the models can be found in the initial article on IsoSim  
456 [21], which has been enhanced with the EMU framework [27] to reduce the size of the  
457 equation system.

458 Note that each flux can be defined either as constant or calculated using a kinetic equation  
459 which may depend on metabolite concentrations. IsoSim can thereby perform both  
460 stoichiometric and kinetic modelling.

461

#### 462 *Design of isotope labeling experiments*

463 The present framework provides i) direct identification of the minimal set of label input(s)  
464 that need to be measured for a given flux model, and ii) simulations for different  
465 configurations (e.g. different pools, flux distributions or local label input dynamics). These

466 two features are crucial to support experimental design and ensure flux identifiability before  
467 performing the experiments [22].

468

469 *Fitting local label input(s)*

470 The labeling dynamics of all the EMUs identified as local label input(s) must be measured or  
471 estimated. IsoSim implements methods to convert these discrete measurements into  
472 continuous analytical functions. It is important to note that neither the analytical function nor  
473 the estimated parameters have any biological meaning. The aim of this step is just to define a  
474 sufficiently accurate representation of the isotopic profiles of the local label input(s).

475 Experimental <sup>13</sup>C-enrichment dynamics of local label input(s) can be fitted by a logistic  
476 function (Eq. 1):

$$477 \quad y(p, t) = \frac{p_1}{1 + e^{-p_2 \cdot (t - p_3)}} \quad (\text{Eq. 1})$$

478 where  $p$  is the vector of parameters to estimate (here  $p_1$ ,  $p_2$  and  $p_3$ ), and  $t$  is time. We also  
479 implemented a double-logistic function (Eq. 2) to fit more complex labeling dynamics, as  
480 proposed by Elmore et al. [38]:

$$481 \quad y(p, t) = p_4 + (p_5 - p_6 \cdot t) \cdot \left( \frac{1}{1 + e^{(p_7 - t)/p_8}} - \frac{1}{1 + e^{(p_9 - t)/p_{10}}} \right) \quad (\text{Eq. 2})$$

482 Parameter estimation is formulated as a constrained non-linear optimization problem (Eq. 3):

$$483 \quad \begin{aligned} & \text{minimize } f(p) \\ & \text{subject to } g(p) > c \end{aligned} \quad (\text{Eq. 3})$$

484 where  $p$  is the parameter vector,  $f$  is the objective function that evaluates the deviation  
485 between the simulated and measured data,  $g(p)$  is the constraint function, and  $c$  is the  
486 constraint vector. The objective function  $f$  (Eq. 4) is defined as the sum of squared weighted  
487 errors:

$$488 \quad f(p) = \sum_i \left( \frac{x_i - y_i(p, t_i)}{\sigma_i} \right)^2 \quad (\text{Eq. 4})$$

489 where  $x_i$  is the experimental value of data point  $i$  collected at time  $t_i$ , with an experimental  
490 standard deviation  $\sigma_i$ , and  $y_i(p, t_i)$  is the corresponding simulated value. Constraints are defined  
491 for all parameters to be estimated ( $0 < p_1 < 1$ ,  $-100 < p_2 < 100$ ,  $-1000 < p_3 < 1000$  for the  
492 logistic function and  $-1 < p_4 < 1$ ,  $-1 < p_5 < 1$ ,  $-10 < p_6 < 10$ ,  $-1000 < p_7 < 1000$ ,  $-100 < p_8 <$   
493  $100$ ,  $-1000 < p_9 < 1000$ ,  $-100 < p_{10} < 100$  for the double logistic function) to improve  
494 convergence by reducing the solution space. The optimization problem is first solved using  
495 particle swarm optimization (R 3.2.4, *pso* package v1.0.3), followed by an L-BFGS-B [39]  
496 search (with an upper limit of 1000 iterations) to improve convergence. A plot of measured  
497 versus fitted data is generated to allow visual inspection of the quality of fit, and the analytical  
498 functions describing local label inputs are provided as output.

499

#### 500 *Simulation of label propagation*

501 IsoSim solves the ODE system to simulate label propagation through the metabolic  
502 subnetwork of interest, using as input i) the constructed model, ii) the analytical functions  
503 describing local label input(s), iii) the metabolite concentrations, and iv) the fluxes. The  
504 simulation engine is based on the fluxomer framework [25], as detailed in [21], and has been  
505 enhanced using the EMU framework [27]. This facilitates the identifiability analysis while  
506 significantly reducing the size of the equation system to be solved.

507

#### 508 <sup>13</sup>C-flux calculation

509 Fluxes are estimated by fitting experimental data (the concentrations and labeling dynamics of  
510 metabolic intermediates). The objective function  $h$  (Eq. 5) is defined as the sum of squared  
511 weighted errors [40]:

$$512 \quad h(v, m) = \sum_i \left( \frac{x_i - y_i(v, m)}{\sigma_i} \right)^2 + \sum_j \left( \frac{n_j - m_j}{\sigma_j} \right)^2 \quad (\text{Eq. 5})$$



513 where  $v$  is the vector of fluxes,  $m$  is the vector of metabolite concentrations  $m_j$ ,  $x_i$  is the  
514 experimental value of the labeling at data point  $i$ , with experimental standard deviation  $\sigma_i$ ,  
515  $y_i(v,m)$  is the corresponding simulated value,  $n_j$  is the experimental concentration of  
516 metabolite  $m_j$  with standard deviation  $\sigma_j$ . Equality and inequality constraints can be defined  
517 for the fluxes (default constraints:  $-10^3 < v < 10^3$ ) and metabolite concentrations (default  
518 constraints:  $10^{-6} < m < 10^3$ ). The objective function  $h$  is minimized using the *nlsic*  
519 optimization algorithm [10] (with 50 iterations). The goodness-of-fit is evaluated using a chi-  
520 square test, and the mean, median, standard deviation and 95% confidence intervals of the  
521 calculated fluxes are estimated using Monte-Carlo sensitivity analysis.

522

### 523 **Author contributions**

524 Funding acquisition, J-C.P. and J.A.V.; Conceptualization and design, P.M., U.S., P.K.,  
525 J.A.V., S.H., and J-C.P.; Investigation, P.M., U.S., P.K., and J-C.P.; Methodology, P.M., U.S.,  
526 P.K., and J-C.P.; Software, P.M.; Visualization, P.M.; Writing - original draft preparation,  
527 P.M.; Writing - review & editing, P.M., U.S., P.K., J.A.V., S.H., and J-C.P.; Supervision, J-  
528 C.P. All authors read and approved the final version of this manuscript.

529

### 530 **Funding**

531 This work was supported by the French National Research Agency project ENZINVIVO  
532 (ANR-16-CE11-0022) and ETH Zurich.

533

### 534 **Acknowledgements**

535 We thank MetaToul (Metabolomics & Fluxomics Facilities, Toulouse, France,  
536 [www.metatoul.fr](http://www.metatoul.fr)), which is part of the MetaboHUB-ANR-11-INBS-0010 national  
537 infrastructure ([www.metabohub.fr](http://www.metabohub.fr)), for providing free access to its computational resources.

538 We thank Matthieu Guionnet for technical assistance and Baudoin Delépine for insightful

539 comments on the manuscript. JCP is grateful to the INSERM for funding his temporary full-  
540 time researcher position.

541

## 542 **References**

- 543 1. Heux S, Berges C, Millard P, Portais JC, Letisse F. Recent advances in high-  
544 throughput (13)C-fluxomics. *Curr Opin Biotechnol.* 2017;43:104-9. doi:  
545 10.1016/j.copbio.2016.10.010. PubMed PMID: 27838571.
- 546 2. Kohlstedt M, Becker J, Wittmann C. Metabolic fluxes and beyond-systems biology  
547 understanding and engineering of microbial metabolism. *Appl Microbiol Biotechnol.*  
548 2010;88(5):1065-75. Epub 2010/09/08. doi: 10.1007/s00253-010-2854-2. PubMed PMID:  
549 20821203.
- 550 3. Yao R, Li J, Feng L, Zhang X, Hu H. (13)C metabolic flux analysis-guided metabolic  
551 engineering of *Escherichia coli* for improved acetol production from glycerol. *Biotechnology*  
552 *for biofuels.* 2019;12:29. doi: 10.1186/s13068-019-1372-4. PubMed PMID: 30805028;  
553 PubMed Central PMCID: PMC6373095.
- 554 4. Revelles O, Millard P, Nougayrede JP, Dobrindt U, Oswald E, Letisse F, et al. The  
555 carbon storage regulator (Csr) system exerts a nutrient-specific control over central  
556 metabolism in *Escherichia coli* strain Nissle 1917. *PLoS One.* 2013;8(6):e66386. doi:  
557 10.1371/journal.pone.0066386. PubMed PMID: 23840455; PubMed Central PMCID:  
558 PMC3688793.
- 559 5. Enjalbert B, Millard P, Dinclaux M, Portais JC, Letisse F. Acetate fluxes in  
560 *Escherichia coli* are determined by the thermodynamic control of the Pta-AckA pathway.  
561 *Scientific reports.* 2017;7:42135. doi: 10.1038/srep42135. PubMed PMID: 28186174;  
562 PubMed Central PMCID: PMC5301487.
- 563 6. Haverkorn van Rijsewijk BR, Kochanowski K, Heinemann M, Sauer U. Distinct  
564 transcriptional regulation of the two *Escherichia coli* transhydrogenases PntAB and UdhA.  
565 *Microbiology.* 2016;162(9):1672-9. doi: 10.1099/mic.0.000346. PubMed PMID: 27488847.
- 566 7. Antoniewicz MR. A guide to (13)C metabolic flux analysis for the cancer biologist.  
567 *Experimental & molecular medicine.* 2018;50(4):19. doi: 10.1038/s12276-018-0060-y.  
568 PubMed PMID: 29657327; PubMed Central PMCID: PMC5938039.
- 569 8. Hui S, Ghergurovich JM, Morscher RJ, Jang C, Teng X, Lu W, et al. Glucose feeds  
570 the TCA cycle via circulating lactate. *Nature.* 2017;551(7678):115-8. doi:  
571 10.1038/nature24057. PubMed PMID: 29045397; PubMed Central PMCID: PMC5898814.
- 572 9. Wittmann C. Fluxome analysis using GC-MS. *Microb Cell Fact.* 2007;6:6. Epub  
573 2007/02/09. doi: 10.1186/1475-2859-6-6. PubMed PMID: 17286851; PubMed Central  
574 PMCID: PMC1805451.
- 575 10. Sokol S, Millard P, Portais JC. influx\_s: increasing numerical stability and precision  
576 for metabolic flux analysis in isotope labeling experiments. *Bioinformatics.* 2012;28(5):687-  
577 93. Epub 2012/01/03. doi: 10.1093/bioinformatics/btr716. PubMed PMID: 22210866.
- 578 11. Weitzel M, Noh K, Dalman T, Niedenfuhr S, Stute B, Wiechert W. 13CFLUX2--high-  
579 performance software suite for (13)C-metabolic flux analysis. *Bioinformatics.*  
580 2013;29(1):143-5. Epub 2012/11/01. doi: 10.1093/bioinformatics/bts646. PubMed PMID:  
581 23110970; PubMed Central PMCID: PMC3530911.
- 582 12. Noh K, Wiechert W. The benefits of being transient: isotope-based metabolic flux  
583 analysis at the short time scale. *Appl Microbiol Biotechnol.* 2011;91(5):1247-65. Epub  
584 2011/07/07. doi: 10.1007/s00253-011-3390-4. PubMed PMID: 21732247.

- 585 13. Noh K, Wahl A, Wiechert W. Computational tools for isotopically instationary  $^{13}\text{C}$   
586 labeling experiments under metabolic steady state conditions. *Metab Eng.* 2006;8(6):554-77.  
587 Epub 2006/08/08. doi: 10.1016/j.ymben.2006.05.006. PubMed PMID: 16890470.
- 588 14. Young JD, Walther JL, Antoniewicz MR, Yoo H, Stephanopoulos G. An elementary  
589 metabolite unit (EMU) based method of isotopically nonstationary flux analysis. *Biotechnol*  
590 *Bioeng.* 2008;99(3):686-99. Epub 2007/09/06. doi: 10.1002/bit.21632. PubMed PMID:  
591 17787013.
- 592 15. Sauer U, Lasko DR, Fiaux J, Hochuli M, Glaser R, Szyperski T, et al. Metabolic flux  
593 ratio analysis of genetic and environmental modulations of *Escherichia coli* central carbon  
594 metabolism. *J Bacteriol.* 1999;181(21):6679-88. Epub 1999/11/05. PubMed PMID:  
595 10542169; PubMed Central PMCID: PMC94132.
- 596 16. Fischer E, Sauer U. Metabolic flux profiling of *Escherichia coli* mutants in central  
597 carbon metabolism using GC-MS. *Eur J Biochem.* 2003;270(5):880-91. Epub 2003/02/27.  
598 doi: 3448 [pii]. PubMed PMID: 12603321.
- 599 17. Yuan J, Bennett BD, Rabinowitz JD. Kinetic flux profiling for quantitation of cellular  
600 metabolic fluxes. *Nat Protoc.* 2008;3(8):1328-40. Epub 2008/08/21. doi:  
601 10.1038/nprot.2008.131. PubMed PMID: 18714301; PubMed Central PMCID: PMC2710581.
- 602 18. Feng X, Page L, Rubens J, Chircus L, Colletti P, Pakrasi HB, et al. Bridging the gap  
603 between fluxomics and industrial biotechnology. *J Biomed Biotechnol.* 2010;2010:460717.  
604 doi: 10.1155/2010/460717. PubMed PMID: 21274256; PubMed Central PMCID:  
605 PMC3022177.
- 606 19. Yuan J, Doucette CD, Fowler WU, Feng XJ, Piazza M, Rabitz HA, et al.  
607 Metabolomics-driven quantitative analysis of ammonia assimilation in *E. coli*. *Mol Syst Biol.*  
608 2009;5:302. doi: 10.1038/msb.2009.60. PubMed PMID: 19690571; PubMed Central PMCID:  
609 PMC2736657.
- 610 20. Le Novere N, Hucka M, Mi H, Moodie S, Schreiber F, Sorokin A, et al. The Systems  
611 Biology Graphical Notation. *Nat Biotechnol.* 2009;27(8):735-41. doi: 10.1038/nbt.1558.  
612 PubMed PMID: 19668183.
- 613 21. Millard P, Portais JC, Mendes P. Impact of kinetic isotope effects in isotopic studies of  
614 metabolic systems. *BMC Syst Biol.* 2015;9:64. doi: 10.1186/s12918-015-0213-8. PubMed  
615 PMID: 26410690; PubMed Central PMCID: PMC4583766.
- 616 22. Millard P, Sokol S, Letisse F, Portais JC. IsoDesign: a software for optimizing the  
617 design of  $^{13}\text{C}$ -metabolic flux analysis experiments. *Biotechnol Bioeng.* 2014;111(1):202-8.  
618 doi: 10.1002/bit.24997. PubMed PMID: 23893473.
- 619 23. Noh K, Wiechert W. Experimental design principles for isotopically instationary  $^{13}\text{C}$   
620 labeling experiments. *Biotechnol Bioeng.* 2006;94(2):234-51. Epub 2006/04/07. doi:  
621 10.1002/bit.20803. PubMed PMID: 16598793.
- 622 24. Crown SB, Antoniewicz MR. Selection of tracers for  $^{13}\text{C}$ -metabolic flux analysis  
623 using elementary metabolite units (EMU) basis vector methodology. *Metab Eng.*  
624 2012;14(2):150-61. Epub 2012/01/03. doi: 10.1016/j.ymben.2011.12.005. PubMed PMID:  
625 22209989.
- 626 25. Srouf O, Young JD, Eldar YC. Fluxomers: A new approach for  $^{13}\text{C}$  metabolic flux  
627 analysis. *BMC Syst Biol.* 2011;5(1):129. Epub 2011/08/19. doi: 10.1186/1752-0509-5-129.  
628 PubMed PMID: 21846358.
- 629 26. Kajihata S, Furusawa C, Matsuda F, Shimizu H. OpenMebius: an open source  
630 software for isotopically nonstationary  $^{13}\text{C}$ -based metabolic flux analysis. *BioMed research*  
631 *international.* 2014;2014:627014. doi: 10.1155/2014/627014. PubMed PMID: 25006579;  
632 PubMed Central PMCID: PMC4071984.
- 633 27. Antoniewicz MR, Kelleher JK, Stephanopoulos G. Elementary metabolite units  
634 (EMU): a novel framework for modeling isotopic distributions. *Metab Eng.* 2007;9(1):68-86.

- 635 doi: 10.1016/j.ymben.2006.09.001. PubMed PMID: 17088092; PubMed Central PMCID:  
636 PMC1994654.
- 637 28. Mottelet S. Fast computation of gradient and sensitivity in  $^{13}\text{C}$  metabolic flux analysis  
638 instationary experiments using the adjoint method. arXiv. 2012;(1206.5072).
- 639 29. Antoniewicz MR, Kelleher JK, Stephanopoulos G. Determination of confidence  
640 intervals of metabolic fluxes estimated from stable isotope measurements. *Metab Eng.*  
641 2006;8(4):324-37. Epub 2006/04/25. doi: 10.1016/j.ymben.2006.01.004. PubMed PMID:  
642 16631402.
- 643 30. Heuillet M, Bellvert F, Cahoreau E, Letisse F, Millard P, Portais JC. Methodology for  
644 the validation of isotopic analyses by mass spectrometry in stable-isotope labeling  
645 experiments. *Anal Chem.* 2018;90(3):1852-60. doi: 10.1021/acs.analchem.7b03886. PubMed  
646 PMID: 29260858.
- 647 31. Wu L, Mashego MR, van Dam JC, Proell AM, Vinke JL, Ras C, et al. Quantitative  
648 analysis of the microbial metabolome by isotope dilution mass spectrometry using uniformly  
649  $^{13}\text{C}$ -labeled cell extracts as internal standards. *Anal Biochem.* 2005;336(2):164-71. Epub  
650 2004/12/29. doi: 10.1016/j.ab.2004.09.001. PubMed PMID: 15620880.
- 651 32. Castaño-Cerezo S, Kulyk-Barbier H, Millard P, Portais JC, Heux S, Truan G, et al.  
652 Functional analysis of isoprenoid precursors biosynthesis by quantitative metabolomics and  
653 isotopologue profiling. *Metabolomics.* 2019. Epub 2019. doi: 10.1007/s11306-019-1580-8.
- 654 33. Cheah YE, Young JD. Isotopically nonstationary metabolic flux analysis (INST-  
655 MFA): putting theory into practice. *Curr Opin Biotechnol.* 2018;54:80-7. doi:  
656 10.1016/j.copbio.2018.02.013. PubMed PMID: 29522915.
- 657 34. Kiefer P, Schmitt U, Muller JE, Hartl J, Meyer F, Ryffel F, et al. DynaMet: a fully  
658 automated pipeline for dynamic LC-MS data. *Anal Chem.* 2015;87(19):9679-86. doi:  
659 10.1021/acs.analchem.5b01660. PubMed PMID: 26366644.
- 660 35. Huang X, Chen YJ, Cho K, Nikolskiy I, Crawford PA, Patti GJ. X13CMS: global  
661 tracking of isotopic labels in untargeted metabolomics. *Anal Chem.* 2014;86(3):1632-9. doi:  
662 10.1021/ac403384n. PubMed PMID: 24397582; PubMed Central PMCID: PMC3982964.
- 663 36. Capellades J, Navarro M, Samino S, Garcia-Ramirez M, Hernandez C, Simo R, et al.  
664 geoRge: A Computational Tool To Detect the Presence of Stable Isotope Labeling in LC/MS-  
665 Based Untargeted Metabolomics. *Anal Chem.* 2016;88(1):621-8. doi:  
666 10.1021/acs.analchem.5b03628. PubMed PMID: 26639619.
- 667 37. Young JD. INCA: a computational platform for isotopically non-stationary metabolic  
668 flux analysis. *Bioinformatics.* 2014;30(9):1333-5. doi: 10.1093/bioinformatics/btu015.  
669 PubMed PMID: 24413674; PubMed Central PMCID: PMC3998137.
- 670 38. Elmore AJ, Guinn SM, Minsley BJ, Richardson AD. Landscape controls on the timing  
671 of spring, autumn, and growing season length in mid-Atlantic forests. *Global Change Biol.*  
672 2012;18(2):656-74. doi: 10.1111/j.1365-2486.2011.02521.x. PubMed PMID:  
673 WOS:000299042500022.
- 674 39. Byrd RH, Lu PH, Nocedal J, Zhu CY. A limited memory algorithm for bound  
675 constrained optimization. *Siam J Sci Comput.* 1995;16(5):1190-208. PubMed PMID:  
676 ISI:A1995RR54100011.
- 677 40. Millard P, Massou S, Wittmann C, Portais JC, Letisse F. Sampling of intracellular  
678 metabolites for stationary and non-stationary ( $^{13}\text{C}$ ) metabolic flux analysis in *Escherichia*  
679 *coli*. *Anal Biochem.* 2014;465:38-49. doi: 10.1016/j.ab.2014.07.026. PubMed PMID:  
680 25102204.

681

682 **Supporting Information**

683 **S1 Table. Initial values of fluxes and metabolite concentrations.** Values of fluxes and  
684 metabolite concentrations used to simulate label propagation through the example network  
685 shown in Fig 1A.

686 **S1 Fig. Simulation results.** Labeling dynamics in response to a switch from unlabeled  $X_{out}$  to  
687 fully labeled  $X_{out}$ .

688 **S2 Fig. Fit of local label inputs.** The labeling dynamics of the local label inputs in all the  
689 subsystems shown in Fig 3 were fitted with analytical functions. The dots represent the fitted  
690 data and the lines represent the best fits.

691 **S3 Fig. Flux calculation results.** Fluxes were estimated by fitting the labeling dynamics of  
692 the metabolic intermediates of all the subsystems shown in Fig 3. The dots represent the fitted  
693 data and the lines represent the best fits.